HOUSING CONDITIONS OF RURAL HOUSEHOLDS IN POLAND COMPA RED WITH SELECTED COUNTRIES OF THE EUROPEAN UNION

Author(s):  
Agnieszka Siedlecka

The aim of the paper was to analyze the housing conditions of households living in rural areas in Poland against a background in selected European Union countries. The household as a basic subject of economic life has limited resources. One of the elements of these resources is a flat. Both its area, equipment and infrastructure are an important element affecting the quality of life. The analysis of statistical data showed that worse conditions, described using the average number of rooms per person in households, were in Poland in comparison with other European Union countries. The statistical data for 2017 collected by the Statistical Office of the European Union (Eurostat) were used in the article.

2020 ◽  
Vol 23 (3) ◽  
pp. 63-73
Author(s):  
Edyta Dworak

Knowledge and innovations are considered to be among the most important factors that determine the pace and quality of economic growth. Therefore, Poland is facing a serious challenge to effectively transform its economy into an innovative economy capable of competing with the most developed countries. The aim of the paper is to present the results of analysis aimed at estimating the innovation gap between Poland and the European Union countries on the basis of the Summary Innovation Index (SII), which was developed by the European Commission within the European Innovation Scoreboard (EIS) in the years 2010–2018. It reviewed the literature on the innovativeness of economies and the innovation gap. Descriptive analysis, statistical data analysis and comparative analysis methods were applied. Statistical data from the European Innovation Scoreboard 2019 were used. The paper formulates a research thesis that assumes that the level of innovativeness of the Polish economy in the analyzed period remained at a lower level than the EU average and therefore there is still an innovation gap between the Polish economy and the average for European Union countries. The results of the analysis confirm this thesis.


2015 ◽  
Vol 61 (4) ◽  
pp. 19-34 ◽  
Author(s):  
B. Hoła ◽  
M. Szóstak

The article presents an analysis and evaluation of the accident rate in selected European Union countries. On the basis of available statistical data, the analysis of accidents in various sectors of the European Union economy was carried out. Afterwards, a ranking of countries regarding accidents in the construction industry was developed. For the selected representative countries, analysis of changes in the indicators which characterize the accident rate during the period between 2008 and 2012 was carried out. Conclusions resulting from the conducted research were formulated.


2009 ◽  
Vol 19 (4) ◽  
pp. 588-593 ◽  
Author(s):  
William C. Stewart ◽  
Bonnie Kruft ◽  
Lindsay A. Nelson ◽  
Jeanette A. Stewart

Purpose To survey ophthalmologists in the European Union to determine their fixed combination (FC) preferences. Methods A multiple-choice survey was sent to randomly chosen ophthalmologists throughout the European Union and bordering countries by electronic mail delivery. Ophthalmologists were resent the survey on two more occasions if no response was obtained. Results In total, 50 surveys were received from 530 distributed (9.4% response) from 16 countries. More ophthalmologists prescribed an FC as second (80%) or third choice (64%) therapy than first choice (30%, p=0.0036). As first (p<0.0001) and third choice (p=0.011), the dorzolamide/timolol FC was most commonly prescribed, while as second choice the latanoprost/timolol FC (p<0.0001) was most popular. Overall, 98% (49/50) of doctors believed FC therapy improved patient care most often by better compliance (n=49) and quality of life (n=48, p<0.0001). Most ophthalmologists believed that there was a difference in efficacy between the FC products (32/50, 64%) with the most effective being the bimatoprost/timolol FC (n=12, 24%, p=0.029). However, fewer ophthalmologists perceived safety differences between the products (34/50, 68%). For prostaglandins, dosing time was suggested in the morning by 18 (36%) ophthalmologists and in the evening by 24 (48%) (p=0.35). Conclusions FCs in the European Union are a potentially popular method to reduce intraocular pressure, being prescribed most commonly as second or third choice therapy. The perceived advantages to FC therapy are greater compliance to the medicine and improved patient quality of life.


BMJ Open ◽  
2018 ◽  
Vol 8 (7) ◽  
pp. e021346 ◽  
Author(s):  
Anna Alonso-Solís ◽  
Katya Rubinstein ◽  
Iluminada Corripio ◽  
Erika Jaaskelainen ◽  
Annika Seppälä ◽  
...  

IntroductionTreatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia(m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform a feasibility study before the cost-effectiveness testing stage.Methods and analysisThis manuscript describes the protocol for a prospective multicentre feasibility study in 45 patients with TRS and their caregivers who will be attended in the public health system of three localities: Hospital Santa Creu Sant Pau (Spain), Semmelweis University (Hungary) and Gertner Institute & Sheba Medical Center (Israel). The primary aim is to investigate the feasibility and acceptability of the m-RESIST solution, configured by three mHealth tools: an app, wearable and a web-based platform. The solution collects data about acceptability, usability and satisfaction, together with preliminary data on perceived quality of life, symptoms and economic variables. The secondary aim is to collect preliminary data on perceived quality of life, symptoms and economic variables.Ethics and disseminationThis study protocol, funded by the Horizon 2020 Programme of the European Union, has the approval of the ethics committees of the participating institutions. Participants will be fully informed of the purpose and procedures of the study, and signed inform consents will be obtained. The results will be published in peer-reviewed journals and presented in scientific conferences to ensure widespread dissemination.Trial registration numberNCT03064776; Pre-results.


2019 ◽  
Vol 60 (4) ◽  
pp. 31-44
Author(s):  
Barbara Chmielewska ◽  
◽  
Józef Stanisław Zegar ◽  

2020 ◽  
Vol 60 (1) ◽  
pp. 661-681 ◽  
Author(s):  
Alpana Mair ◽  
Martin Wilson ◽  
Tobias Dreischulte

Polypharmacy describes the concomitant use of multiple medicines and represents a growing global challenge attributable to aging populations with an increasing prevalence of multimorbidity. Polypharmacy can be appropriate but is problematic when the increased risk of harm from interactions between drugs or between drugs and diseases or the burden of administering and monitoring medicines outweighs plausible benefits. Polypharmacy has a substantial economic impact in service demand and hospitalization as well as a detrimental impact on patients’ quality of life. Apart from causing avoidable harm, polypharmacy can also lead to therapeutic failure, with up to 50% of patients who take four or more medications not taking them as prescribed. Guidance is needed to support patients and clinicians in defining and achieving realistic goals of drug treatment, and system change is necessary to aid implementation. This article outlines lessons from two programs that aim to address these challenges: the Scottish polypharmacy guidance on realistic prescribing and the European Union SIMPATHY project.


2009 ◽  
Vol 43 (10) ◽  
pp. 1275-1289 ◽  
Author(s):  
Mark Shucksmith ◽  
Stuart Cameron ◽  
Tanya Merridew ◽  
Florian Pichler

Sign in / Sign up

Export Citation Format

Share Document